Smith & Nephew stock costs EUR 12.15 ahead of results

Published on 10/06/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 4.60 percent to USD 3.097 billion. Smith & Nephew stock is EUR 12.15 on October 6, 2026 versus EUR 12.05.

Flatlay mit Aktienzertifikat, ISIN-Karte, Implantatschrauben und Verbandsmaterial — Smith & Nephew plc (ISIN GB0009223206) steht für Wundversorgung, dargestellt als Flatlay mit Zertifikat, Schrauben, Illustration mit AI erstellt.

Smith & Nephew (ISIN GB0009223206) was trading at EUR 12.15 at Lang & Schwarz on October 6, 2026 at 11:03 a.m. CEST, up 0.83 percent versus the prior close of EUR 12.05. The company's investor calendar sets the third-quarter 2026 trading report for November 4, 2026, according to Smith & Nephew.

First-half revenue rose 4.60 percent

Smith & Nephew reported USD 3.097 billion of revenue in the first half of 2026, compared with USD 2.961 billion in the first half of 2025. That produced reported growth of 4.60 percent, while underlying growth was 2.30 percent, according to Smith & Nephew.

Operating profit increased to USD 448 million from USD 429 million in the first half of 2025. Trading profit rose 8.10 percent to USD 566 million from USD 523 million, and the trading profit margin expanded to 18.30 percent from 17.70 percent.

Profit growth faces a slower outlook

The first-half figures show a wider profit improvement than the revenue increase, but the company also expects different growth rates across the year. Smith & Nephew's investor materials project underlying growth of 5.00 percent to 5.50 percent in the second half of 2026, alongside full-year free cash flow guidance of USD 800 million.

Efficiency savings are another quantified support for profitability. The company expects total 2026 savings of USD 200 million after identifying an additional USD 50 million opportunity, while the net tariff impact is expected to be broadly neutral because of refunds.

London listing anchors the stock

A September 18, 2026 filing identifies Smith & Nephew's ordinary shares under ISIN GB0009223206 and confirms admission to the London Stock Exchange Main Market, according to the SEC. The investor-relations page also identifies the company as a FTSE 100 constituent and describes three operating units: Advanced Wound Management, Sports Medicine and ENT, and Orthopaedics.

EUR 12.15 in trading

At Lang & Schwarz, Smith & Nephew stock was trading at EUR 12.15 on October 6, 2026 at 11:03 a.m. CEST, up 0.83 percent versus the EUR 12.05 prior close.

The further course of trading is shown by the continuously updated real-time quote of Smith & Nephew stock.